<DOC>
	<DOC>NCT00147121</DOC>
	<brief_summary>To establish standard therapy for patients with advanced-stage low grade B-cell lymphoma</brief_summary>
	<brief_title>Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)</brief_title>
	<detailed_description>Since currently there is no standard therapy for untreated advanced-stage low-grade B-cell lymphoma, Phase 2/3 study was planned. Comparison(s): An intensified bi-weekly version by shortening the intervals of both rituximab and CHOP therapies using G-CSF, compared to the tri-weekly R-CHOP regimen.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. Histological confirmed, lowgrade Bcell lymphoma except mantle cell lymphoma and histologic transformation to DLBCL 2. CD20positive 3. Ann Arbor CS III or IV 4. Lymphoma cell count in PBâ‰¦10,000/mm3 5. 20&lt;=age&lt;=69 6. ECOG PS 02 7. Bidimensionally measurable disease &gt;1.5cm in a single dimension by CT scans 8. No prior chemotherapy, radiotherapy, interferonalfa, or antibody therapy 9. Normal BM, hepatic, renal, cardiac, and pulmonary function 10. Written informed consent 1. CNS involvement 2. Glaucoma 3. DM treated by insulin 4. Uncontrollable HT 5. AP, AMI 6. Positive HBs antigen 7. seropositive to HCV 8. seropositive to HIV 9. Interstitial pneumonitis, pulmonary fibrosis, or emphysema 10. Severe infection 11. Liver cirrhosis 12. Double cancer 13. Pregnant or lactating 14. Patients who desire auto PBST after CR 15. Patients treated with major tranquilizer or antidepressant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>CHOP</keyword>
	<keyword>Bi-weekly</keyword>
	<keyword>low-grade B-cell lymphoma</keyword>
	<keyword>advanced stage</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Untreated stage III/IV low-grade B-cell lymphoma</keyword>
</DOC>